Serious but less common adverse effects include pancreatitis, gallbladder disease, acute kidney injury (particularly in the setting of dehydration from gastrointestinal symptoms), and hypoglycemia when used in combination with insulin or sulfonylureas
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
Depending on the online service, GLP-1 medications are available as soon as one to 2 days with shipping or to pick up in person at a pharmacy
(Source: KFF, 2026) Prior Authorization, Denials & Appeal Success Rates Having coverage on paper is not the same as getting a prescription filled
Published online January 2, 2026:10600280251407145
